The 7 most recent market catalysts affecting $SCNI, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 7, 2026
Corporate Catalyst
Bullish
Impact 75
Scinai Immunotherapeutics Reports Nine-Month 2026 Financial Results and CDMO Expansion
Scinai Immunotherapeutics announced a substantial 167% increase in revenue for the nine months ended September 30, 2026, reaching $2.80 million, largely attributed to the integrati…
Oct 16, 2026
Corporate Catalyst
Bearish
Impact 75
Scinai Immunotherapeutics shares are trading lower after the company announced the closing of a $4 million financing through a private placement and warrant exercise transactions.
The immediate negative market reaction to Scinai Immunotherapeutics' financing announcement suggests that investors perceive the terms of the private placement and warrant exercise…
Oct 13, 2026
Corporate Catalyst
Bullish
Impact 85
Scinai Immunotherapeutics shares are trading higher after the company announced a development and manufacturing agreement with a biopharma company, boosting committed customer orders to $7.6 million, up 300% from year-end 2025.
This headline represents a significant positive corporate catalyst for Scinai Immunotherapeutics. The 300% increase in committed customer orders to $7.6 million, albeit from a futu…
Oct 13, 2026
Corporate Catalyst
Bullish
Impact 55
Scinai Expands CDMO Business with $5.1M Development and Clinical Manufacturing Agreement
This headline is a positive corporate catalyst for Scinai (SCNI) as it secures a new revenue-generating agreement in the growing CDMO space. The $5.1 million deal, while not massiv…
Sep 24, 2026
Corporate Catalyst
Neutral
Impact 55
Scinai Files Prospectus For Resale Of Up To 2,706,450 ADS By YA II PN
Scinai Technologies has filed a prospectus for the resale of up to 2,706,450 ADSs by YA II PN, Ltd. This filing is a standard procedure required when a large investor, often a fina…
Aug 24, 2026
Corporate Catalyst
Bullish
Impact 75
Scinai Immunotherapeutics H1 Net Income $1.6M Vs Loss $4.1M Prior Year; Revenues $949K Up From $773K YoY; Continues To Pursue ~$5M In CDMO Revenues For 2026
Scinai Immunotherapeutics reported a net income of $1.6 million for the first half of 2026, a notable improvement from a $4.1 million loss in the prior year. However, this positive…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 75
Scinai Immunotherapeutics shares are trading higher after the company announced a 1‑for‑10 ADS reverse split effective August 21.
A reverse stock split, while often seen as a negative signal, can sometimes lead to a short-term positive reaction as the share price increases, potentially making the stock more a…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.